[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Institut National de la Santé Et de la Recherche Médicale, France\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":650},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,79,0,25,[9,45,70,96,120,139,166,191,229,259,279,300,334,366,395,423,444,468,489,511,528,558,578,604,628],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":21,"targetDuration":24,"studyType":25,"phases":4,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100430690","french-parkinsons-disease-cohort---ns-park-100430690",false,"NCT04888364","French Parkinson's Disease Cohort - NS-PARK","Cohort of the French Clinical Research Network for Parkinson's Disease (NS-PARK Cohort)","NS-PARK","Inclusion Criteria:\n\n* Diagnosis of Parkinson's disease according to UK PD brain bak criteria\n* OR diagnosis of parkinsonian syndrome: multiple system atrophy, progressive supranuclear palsy, dementia with Lewy body, or corticobasal syndrom\n* OR Subjects at risk of PD defined as :\n\nNo symptom or diagnosis of Parkinson's disease nor parkinsonian syndrome, and relative to a patient with a diagosis of PD or parkinsonian syndrome, or carrier of a known mutation responsible for a genetic form of PD or patient with a diagnosis of idiopathic REEM sleep disorder or prodromal form of PD as defined by MDS criteria (Berg et al., 2015)\n\nAND for all participants\n\n* Affiliated to social security\n* Age \\> 10 years\n\nExclusion Criteria:\n\n* Subject under legal protection\n* Subject who do not consent to the research\n* for the optional skin biopsy only: clinically significant coagulation abnormalities or anticoagulant treatment",true,"ALL","10 Years",{"count":22,"type":23},30000,"ESTIMATED","15 Years","OBSERVATIONAL","The aim of NS-PARK cohort are to describe the natural history of Parkinson's disease (PD), and to propose patients stratification models based on PD pathophysiological mechanisms. Patients are included at all PD expert centers in France. Standardized demographic, diagnosis, motor and non-motor symptoms evaluation, and treatment information are collected, and clinical data are updated at each visit of the patient at the center. A blood sampling is perform at baseline for genetic testing and implement an associated biocollection.",[28],"Parkinson Disease",[30,31],"Parkinson's disease","Genetics","RECRUITING","2026-08-19",{"date":35,"type":36},"2026-08-20","ACTUAL",{"date":38,"type":36},"2021-06-16",{"date":40,"type":23},"2034-12-31",{"name":42,"class":43},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":18,"sex":19,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":63,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100374033","mechanisms-of-neuronal-resilience-in-alzheimers-disease-and-its-focal-variants-a-petmr-study-100374033","NCT04150198","MECHANISMS OF NEURONAL RESILIENCE IN ALZHEIMER'S DISEASE AND ITS FOCAL VARIANTS: A PET\u002FMR STUDY","PET-AL","Inclusion Criteria:\n\n1. For all subjects:\n\n   * Affiliation to a social security insurance or beneficiary\n   * Informed consent form signed by the participant or his \u002F her legal representative\n   * Participants aged 40 to 80 years.\n2. Selection of AD-Y group\n\n   \\- In vivo proof of Alzheimer's pathology:\n   * Determination of specific proteins on the cerebrospinal fluid (CSF, a routine care procedure). The values considered pathological (AD) are Aβ1-42 peptide \\\u003C500 (μg \u002F ml), and \u002F or tau protein\\> 450 and phosphorylated tau protein\\> 60, IATI index \\\u003C1, tau \u002F Aβ protein ratios \\> 1.23 as well as phosphorylated tau protein \u002F Aβ1-42\\> 0.211.\n   * And \u002F or a positive PET-amyloid imaging test.\n   * Early-onset episodic memory deficit (\\\u003C65 years), progressive onset with evidence of hippocampal amnesic syndrome at neuropsychological assessment.\n\n   In memory tests, the amnesic hippocampal syndrome is defined by: a deficit of the free recall despite a reinforced encoding, an effectiveness of the indexing or an impairment of the recognition capabilities, the presence of intrusions. The presence during the tests of false memories spontaneous (intrusions) or provoked (false recognitions) is also very contributive to the definition of amnesic syndrome of the hippocampal type.\n3. PCA group selection\n\n   Patients with a clinical and cognitive profile suggestive of PCA, characterized by:\n   * an in vivo proof of the Alzheimer pathology (see selection of the AD-Y group)\n   * a specific impairment of neuro-visual abilities, in the absence of major disorders of episodic memory (hippocampal) and executive functions.\n\n   Two possible variants:\n   * occipito-temporal variant: visuo-perceptive deficit in the foreground, early onset and progressive worsening; lack of visual identification of objects, symbols, words or faces;\n   * biparietal variant: visuospatial deficit in the foreground, early settlement and progressive worsening; Gerstmann syndrome; Balint syndrome; gestural apraxia; visual-spatial neglect.\n4. Selection of the control subjects group\n\n   * Normal neurological and neuropsychological examinations.\n   * Control subjects will be matched in age to patients.\n\nNon-inclusion Criteria:\n\n1. General non-inclusion criteria:\n\n   * Medical history of torsade de pointe or risk of torsade de pointes\n   * Patient treated with drugs known to lengthen QT (see www.crediblemeds.org)\n   * Contraindication to radiopharmaceutical injection:\n\n   For precautions of safety of use of the radiopharmaceutical, a blood sample allowing to check the renal and hepatic functions will be realized before imagery. The delay between the sampling and the neuroimaging visit is left to the investigator's discretion based on the patient's biological results. In particular, the glomerular filtration rate will be calculated from the results obtained.\n\n   In the event of renal insufficiency (GFR 30mL \u002F min \u002F 1.73m2), hepatic insufficiency or any other biological anomaly of grade 3 or higher detected during these analyzes, the participant will not be able to carry out PET imaging. In this case, the results of the analyzes will be sent to the doctor indicated by the participant. This evaluation, which involves a determination of serum creatinine, is part of the standard routine biological assessment performed in the context of cognitive disorders\n\n   Inability to provide informed consent by participant or legal representative:\n   * Patient deprived of liberty by decision of justice or not benefiting from social cover.\n   * Person in the process of participating in another therapeutic research or in a period of exclusion from another research.\n   * Participants with a contraindication to MRI: pacemaker or cardiac defibrillator, implanted equipment activated by an electrical, magnetic or mechanical system, haemostatic clips of intracerebral aneurysms or carotid arteries , carriers of orthopedic implants.\n   * Contraindication to radiopharmaceutical injection: known hypersensitivity to the active substance or to any of the excipients, renal impairment (GFR 30mL \u002F min \u002F 1.73m2), hepatic insufficiency or any other biological abnormality of grade 3 or higher\n   * Person suffering from claustrophobia.\n   * Pregnancy (for women of childbearing age, a urine pregnancy test will be performed on the day of the inclusion visit and the PET-MRI examination).\n   * Any symptoms or biological values suggestive of a systemic disorder (renal, hepatic, cardiovascular, pulmonary) or any other medical conditions that could interfere with the interpretation of test results or compromise the health of patients.\n   * Person subject to a legal safeguard.\n2. Specific non-inclusion criteria for AD-Y and PCA patients:\n\n   * Sudden appearance of cognitive deficits.\n   * Gait disturbances, convulsions, major behavior modification.\n   * Focal alterations to neurological examination, extrapyramidal signs, hallucinations, fluctuations. cognitive.\n   * Psychiatric, cerebrovascular, metabolic, inflammatory pathology.\n3. Specific non-inclusion criteria for control subjects:\n\n   * Pathological neurological examination\n   * History of neurological disease (in particular ischemic stroke or neurodegenerative disease) or psychiatric illness (particularly severe depression, psychosis, or bipolar illness still requiring drug treatment at the time of inclusion)\n   * Physical affection that is serious or can interfere with cognitive functions.","40 Years","80 Years",{"count":55,"type":23},45,"INTERVENTIONAL",[58],"NA","Patients with Alzheimer's disease and with early onset of symptoms (\\\u003C65 years) (AD-Y) have a multi-domain cognitive deficit, whereas memory disorders (typical of the elderly patient's AD) are less often in the foreground. In addition, some MA-J have an atypical phenotype indicating focal brain damage, although they have the same pathological lesions: amyloid deposits and tau protein deposition (DNF). This is the case of posterior cortical atrophy (PCA) characterized by complex visual disturbances and atrophy affecting the more posterior regions of the brain. Based on the clinical profile of PCA patients, a more refined anatomo-clinical classification was proposed, distinguishing a rather \"ventral\" form and a rather \"dorsal\" form. The recent arrival of tau-specific PET tracers now makes it possible to evaluate in vivo fibrillary neurodegeneration (FND), which is well correlated with the severity of cognitive disorders. Advances in MRI have shown that each neurodegenerative syndrome targets a large-scale neural network, which in turn shows a vulnerability for a specific biological disease. In the case of AD, the reason for such a difference in cognitive and anatomical impairment between patients with diffuse involvement and others with more focal involvement is not known. One possible explanation is the existence, in focal forms, of neuronal mechanisms that oppose vulnerability. These mechanisms may correspond to the so-called \"resilience\" phenomenon, defined as resistance to a neuropathological process by the ability to optimize cognitive performance via the efficient recruitment of neural networks. The mechanisms underlying resilience in neurodegeneration are unknown. Their identification is very important for the management and treatment of AD.",[61,62],"Alzheimer Disease, Early Onset","Posterior Cortical Atrophy",{"date":35,"type":36},{"date":65,"type":36},"2021-12-08",{"date":67,"type":23},"2029-12-31",{"name":42,"class":43},2,{"id":71,"slug":72,"hasResults":12,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":12,"sex":19,"minAge":4,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":44},"100639061","virological-surveillance-of-acute-respiratory-infection-in-primary-health-care-in-metropolitan-france-100639061","NCT07599449","Virological Surveillance of Acute Respiratory Infection in Primary Health Care in Metropolitan France","RS-viro IRA","Inclusion Criteria:\n\n* be seen by a general practitioner or pediatrician participating in the Sentinelles surveillance program;\n* between week 40 (late September-early October) and week 15 (mid-April) of each year\n* have an acute respiratory infection (ARI) as defined below: Sudden onset of fever (or feeling of fever) and respiratory symptoms\n* have given oral consent to participate in this monitoring or, in the case of minors, oral consent given by the child's legal guardian(s) present at the consultation\n\nExclusion Criteria:\n\n* a person who is subject to a court-ordered protective measure;\n* a person who is under guardianship or conservatorship, unless accompanied by their legal guardian or unless the legal guardian objects to their participation;\n* a person who is not in a condition to receive information or give consent.",{"count":78,"type":23},25000,"Every year in the fall and winter, numerous respiratory viruses (such as influenza viruses, SARS-CoV-2 (COVID-19), RSV, rhinovirus, and metapneumovirus) circulate in mainland France, causing acute respiratory infections (ARIs). These viruses can cause epidemics of varying severity, requiring close monitoring to determine their circulation levels and adapt public health measures accordingly. In France, ARI surveillance relies on two networks: the Sentinelles network in primary care and the RENAL network in hospitals. The Sentinelles surveillance is conducted in collaboration with Santé publique France, the National Reference Center for Respiratory Infection Viruses (Institut Pasteur and Hospices Civils de Lyon), and the University of Corsica. As part of the virological surveillance of ARIs, Sentinelles physicians are asked to collect nasopharyngeal swabs or saliva samples from a sample of patients presenting with an ARI during their clinic visits. This surveillance makes it possible to identify respiratory viruses circulating in primary care (general practice and pediatrics), to describe confirmed cases for each of the circulating viruses, and to estimate the impact of each on general practice. This surveillance also allows for the evaluation of the effectiveness of vaccines against influenza and COVID-19.",[81,82,83,84,85,86,87],"Respiratory Tract Infections (RTI)","Influenza -Like Illness","Influenza","COVID - 19","RSV Infections","Rhinovirus Infection","Metapneumovirus Infection","2026-07-31",{"date":90,"type":36},"2026-08-03",{"date":92,"type":36},"2026-05-14",{"date":94,"type":23},"2031-05-14",{"name":42,"class":43},{"id":97,"slug":98,"hasResults":12,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":18,"sex":19,"minAge":103,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":56,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":44},"100643819","investigating-vascular-properties-of-hemi-and-spg-signals-in-individuals-with-or-at-risk-for-chronic-kidney-disease-100643819","NCT07604922","Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease","STIMULUS-CKD","Inclusion Criteria:\n\n* Common Inclusion Criteria:\n\n  * Adults aged over 18 years, of both sexes\n  * Patients eligible for or affiliated with a social security scheme\n  * Patients who have provided written informed consent to participate in the study\n\nCommon Exclusion Criteria:\n\n* Inability to give informed consent\n* Persons under legal protection (guardianship, trusteeship, or court protection)\n* Language barrier or psychological refusal to read the information\n* Medical conditions with a life expectancy \\\u003C 1 year according to clinical judgment\n* Ongoing participation restriction due to another clinical research study\n* Pregnant women (due to physiological hemodynamic changes in blood pressure and arterial stiffness during pregnancy)\n* Cardiac arrhythmias: current atrial fibrillation or high-degree atrioventricular block\n\nExclusion Criteria:\n\n* Hypertension Group\n\n  * Inclusion: Prior diagnosis of arterial hypertension\n  * Stable cardiovascular treatment in the previous 1 month\n  * Exclusion:\n\n    * CKD with GFR \\\u003C60 mL\u002Fmin\n    * ACR \\> 30 mg\u002Fmmol\n    * Type 2 diabetes Type 2 Diabetes Group\n  * Inclusion:\n  * Prior diagnosis of type 2 diabetes\n  * Stable cardiovascular treatment in the previous 1 month\n  * Exclusion:\n\n    * CKD with GFR \\\u003C 60 mL\u002Fmin\n    * ACR \\> 30 mg\u002Fmmol Moderate CKD Group\n  * Inclusion:\n  * Moderate CKD (eGFR between 30 and 60 mL\u002Fmin) (CKD-EPI)\n  * Patients scheduled for arterial stiffness assessment as part of routine care\n  * Stable cardiovascular treatment in the previous 1 month\n  * Exclusion:\n  * No specific exclusion criteria beyond common exclusions Severe CKD Group\n  * Inclusion:\n\n    * Severe CKD (GFR \\\u003C 30 mL\u002Fmin for ≥ 2 months)\n    * Patients scheduled for arterial stiffness assessment as part of routine care\n    * Stable cardiovascular treatment the previous 1 month\n  * Exclusion: No specific exclusion criteria beyond common exclusions20 \u002F 48 C25-07\\_Protocole\\_ V1.0\\_01.12.2025 Healthy Volunteers Group\n  * Inclusion: No documented chronic disease\n  * Exclusion:\n\n    * Moderate or severe CKD (GFR \\\u003C 60 mL\u002Fmin) (CKD-EPI)\n    * Hypertension\n    * Type 2 diabetes\n    * Stable cardiovascular treatment in the previous 1 month","18 Years",{"count":105,"type":23},165,[58],"This prospective, single-center clinical investigation conducted in France will evaluate two non-invasive investigational devices (HEMI and SPG-NINOX) designed to assess microcirculation in adults. The study will include 165 participants divided into five groups (33 per group): healthy volunteers, patients with hypertension without chronic kidney disease (CKD), patients with type 2 diabetes without CKD, patients with moderate CKD, and patients with severe CKD. The primary objective is to compare baseline small vessel pressure measured with the HEMI (Multi-spectral optical system for microcirculation hemodynamics) device across groups in order to identify microvascular alterations associated with cardiometabolic and renal disease. Secondary objectives include assessment of microvascular responses after post-ischemic hyperemia, evaluation of SPG-derived (Speckle plethysmography) small vessel flow and volume parameters, comparison with reference vascular measurements (including SphygmoCor and ultra-high frequency ultrasound), and evaluation of feasibility, acceptability, and measurement reproducibility. Participation is non-randomized, based on participants' pre-existing clinical condition, and study procedures are non-invasive with an expected visit duration of approximately 60 minutes.",[109,110,111],"Chronic Kidney Disease","Hypertension (HTN)","Type 2 Diabetes Mellitus (T2DM)","NOT_YET_RECRUITING","2026-07-30",{"date":88,"type":36},{"date":116,"type":23},"2026-09-15",{"date":118,"type":23},"2028-09-15",{"name":42,"class":43},{"id":121,"slug":122,"hasResults":12,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":18,"sex":19,"minAge":103,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":56,"phases":129,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":133,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":44},"100588414","nutrition-gut-microbiota-and-health--feces-sample-collection-in-nutrinet-sant-participants-100588414","NCT06941090","Nutrition, Gut Microbiota and Health : Feces Sample Collection in NutriNet-Santé Participants","NUTRIGUT","Inclusion Criteria:\n\n* Participant in the NutriNet-Santé cohort\n* Age ≥ 18 years\n* Resident of metropolitan France\n* Written comprehension frenc\n\nExclusion Criteria:\n\n* Person subject to a safeguard of justice measure\n* Person belonging to one of the categories of vulnerable persons\n* Diagnosis of COVID-19 (clinically or by PCR) in the month prior to collection\n* Contact with a COVID-19 patient in the month prior to collection\n* Suspicion of COVID-19 in the month preceding collection (clinical signs of infection : fever associated with headache, respiratory signs, os anosmia\u002Fageusia)",{"count":128,"type":23},10000,[58],"The gut microbiota is currently attracting increasing attention from the scientific community and also from the general public, as evidence of its role in human physiology has been highlighted. Microbial signatures have also been associated with various pathologies (e.g. obesity, diabetes, gastrointestinal disorders, neurodegenerative diseases), but the causality of these associations is still uncertain. Among the factors that may influence the composition of the gut microbiota (e.g. lifestyle, hygiene, medication, genetics, environment), nutrition would a major role. The major changes in lifestyle and diet observed over recent decades are strongly suspected of disrpting the host-gut microbiota balance.\n\nIn addition to their nutrient content, our diets also contain other bioactive compounds (e.g. polyphenols) and raise new issues (e.g. temporal structure of diets, food processing, presence of additives or contaminants such as pesticide residues, intake of dietary supplements, dietary exclusions, glycemic index) that is necessary to take into account. Thus, it is mandatory to explore and characterize in a more precise way, within large samples consisting of individuals with varied characteristics, the way in which the composition of the gut microbiota is influenced by the host's diet and its health consequences.\n\nThe aim of this research is therefore to study the links between nutrition, gut microbiota profiles and health. To do this, the research will implement large-scale stool sample collection from participants in the NutriNet-Santé cohort (\"Nutrinautes\"), thus constituting a \"microbiota\" sub-cohort.\n\nA target of N=10,000 participants in the NutriNet-Santé cohort will be recruited on a voluntary basis. A selection will then be made among Nutrinautes willing to participate in the research (which may be more numerous than necessary) to maximize the diversity of profiles. Participants will be informed of their selection or non-selection by e-mail. A second stool sample will also be collected 2-3 months after the first for a sub-sample of N=300 to assess intra-individual variability in microbiota profiles. The selected participants will receive a stool self-sampling kit with detailed instructions by post to their home address. The pseudonymized samples will be returned by mail by the participant to the processing laboratory, which will determine their gut microbiota characteristics by 16S rDNA sequencing and\u002For \" shotgun \" sequencing. The gut microbiota profiles will then be analyzed in a pseudonymised manner in association with diet and health, using data collected as part of the NutriNet-Santé cohort follow-up (e.g. food consumption, prevalence and incidence of pathologies, biological data, anthropometric characteristics, medication intake, socio-demographic characteristics, lifestyle).",[132],"Gut Microbiome",{"date":88,"type":36},{"date":135,"type":36},"2023-12-15",{"date":137,"type":23},"2033-12-15",{"name":42,"class":43},{"id":140,"slug":141,"hasResults":12,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":18,"sex":19,"minAge":147,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":151,"conditions":152,"keywords":154,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":160,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":44},"100581416","heat-waves-urban-heat-islands-and-wellbeing-and-health-a-mobile-sensing-approach-100581416","NCT06850025","Heat Waves, Urban Heat Islands, and Wellbeing and Health: a Mobile Sensing Approach","Heat Waves, Urban Heat Islands, and Wellbeing and Health: a Mobile Sensing Approach (H3Sensing)","H3Sensing","Inclusion Criteria:\n\n* Person aged between 30-64 years\n* Person living in the Ile-de-France\n\nExclusion Criteria:\n\n* Person subject to a legal protection measure (safeguarding of justice, curatorship, guardianship)\n* Person deprived of liberty by a judicial or administrative decision,\n* Person with a major functional limitation affecting their spatial mobility\n* Person unable to complete a questionnaire\n* Known cardiovascular (other than hypertension) or cerebrovascular disease: personal history of myocardial infarction, rhythm disorders or stroke\n* People wearing a pacemaker or other implanted device, due to the risk of interference\n* Pregnant or breastfeeding woman\n* Person working night or shift\n* Person with a definite plan to move in the coming months (before the second collection during summer)\n* Person who initially refuses to participate in this second wave of the study\n* Person working outside the Ile de France","30 Years","64 Years",{"count":150,"type":23},180,"The first objective of H3Sensing is to investigate outdoor environmental, building, dwelling, situational, and behavioral determinants of objectively assessed personal heat stress over daily movements during warm periods.\n\nThe second aim is to investigate how these heat stress determinants and momentary and cumulated heat stress itself are related to physiological indicators of heat stress, sleep, thermal discomfort, and well-being.",[153],"General Population, no Specific Condition",[155,156,157,158,159],"Heat waves","Urban Heat Islands","Wellbeing","Health","Thermoregulation",{"date":88,"type":36},{"date":162,"type":36},"2025-02-25",{"date":164,"type":23},"2035-02-25",{"name":42,"class":43},{"id":167,"slug":168,"hasResults":12,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":12,"sex":19,"minAge":174,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":56,"phases":178,"briefSummary":179,"conditions":180,"keywords":182,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":185,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":44},"100526911","bronchial-epithelium-of-children-with-post-infectious-bronchiolitis-obliterans-100526911","NCT06140901","Bronchial Epithelium of Children With Post-infectious Bronchiolitis Obliterans","Morphological and Functional Pilot Study of the Bronchial Epithelium of Children With Post-infectious Bronchiolitis Obliterans","e-PIBO","Inclusion Criteria:\n\n1. Children from 1 month to 6 years hospitalized at the Timone Enfant University Hospital\n2. Diagnosis of an adenovirus or rhinovirus respiratory infection confirmed on a nasal swab, made upon arrival as part of the child's initial care\n3. Consent form read, understood, approved and signed by parents before any study procedure\n4. Affiliation to a social security scheme or beneficiary of such a scheme\n\nThe inclusion criteria for children who were not hospitalized when diagnosed with an adenovirus and rhinovirus respiratory infection at the Timone Enfant University Hospital are:\n\n1. Children from 1 month to 6 years old transferred to the Timone Enfant University Hospital\n2. Show the following signs:\n\n   has. Clinical: clinical signs persist 6 weeks after a viral infection: tachypnea, wheezing and\u002For persistent hypoxemia b. Scan: mosaic appearance +\u002F- bronchiectasis, atelectasis vs. +\u002F- EFR if performed: obstructive ventilatory disorder not or only slightly reversible after bronchodilators\n3. Consent form read, understood, approved and signed by parents before any study procedure\n4. Affiliation to a social security scheme or beneficiary of such a scheme\n\nExclusion Criteria:\n\n1. Refusal of participation in the study by the family will be a reason for non-inclusion, as well as in the absence of parental authority.\n2. The existence of an underlying chronic pulmonary pathology (e.g. cystic fibrosis, ciliary dyskinesia).\n3. A coagulation pathology.","1 Month","6 Years",{"count":177,"type":23},450,[58],"Bronchiolitis obliterans (BO) is an irreversible chronic obstructive pulmonary pathology leading to obstruction and\u002For obliteration of the small airways. In children, the most common form of BO occurs following a serious lower respiratory tract infection. This is a rare complication; the incidence is unknown. The diagnosis, often late, is made on clinical, spirometric and radiological arguments. The pathophysiology would be linked to damage to the airway epithelium. PIBO is most commonly associated with adenovirus (ADV) infection (serotypes 3, 7, 11 and 21) but also other viruses such as rhinovirus (RV). The treatment of PIBO is not clearly established, it remains empirical.\n\nThe research hypothesis is that the morphology of the nasal epithelium of children with ADV or RV infection is different for those progressing to PIBO. The main objective of the proposed observational study is to characterize damage to the respiratory epithelium in these children.\n\nThis is a single-center prospective longitudinal study (AP-HM), in children aged 1 month to 6 years, comparing children hospitalized for lower respiratory infection by ADV or RV progressing or not to PIBO. All children included will have a nasal swab and brushing on D0. Children developing PIBO will have nasal brushing with bronchial endoscopy with bronchial biopsies and bronchoalveolar washing at the time of PIBO diagnosis and again at M6 in case of partial response to treatment.\n\nThis is therefore a pilot study aimed at defining damage to the respiratory epithelium in children with PIBO following an ADV or RV infection and the role of respiratory epithelial cells in PIBO.",[181],"Bronchiolitis Obliterans",[183,184],"children","post infectious",{"date":90,"type":36},{"date":187,"type":36},"2023-12-04",{"date":189,"type":23},"2027-08-02",{"name":42,"class":43},{"id":192,"slug":193,"hasResults":12,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":12,"sex":19,"minAge":4,"maxAge":199,"enrollmentInfo":200,"targetDuration":202,"studyType":25,"phases":4,"briefSummary":203,"conditions":204,"keywords":206,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":222,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":228},"100419822","health-effects-of-cardiac-fluoroscopy-and-modern-radiotherapy-in-pediatrics---radiotherapy-100419822","NCT04746729","Health Effects of CArdiac FluoRoscopy and MOderN RadIotherapy in PediatriCs - Radiotherapy","Health Effects of CArdiac FluoRoscopy and MOderN RadIotherapy in PediatriCs - Radiotherapy (HARMONIC-RT)","HARMONIC-RT","Retrospective inclusion of study participants\n\nInclusion Criteria:\n\n* First external beam radiation therapy (EBRT) started in 2000 or after for management of a first primary neoplasm\n* Age under 22 years at the time of first EBRT initiation\n* Radiation treatment plan (first EBRT) stored in DICOM format\n* Usual residency in the country of EBRT to enable a long-term follow-up\n\nExclusion Criteria:\n\n* Patients with poor prognosis (e.g. diffuse pontine glioma or high grade glioma) at first EBRT initiation\n* Prior external or internal radiation therapy\n* Patients who refused to participate in the study\n\nProspective inclusion of study participants\n\nInclusion Criteria:\n\n* Scheduled first EBRT for management of a first primary neoplasm\n* Age under 22 years at the time of scheduled first EBRT\n* Radiation treatment plan stored in DICOM format\n* Affiliate or beneficiary of health insurance (or any required equivalent as defined in applicable national law)\n* Usual residency in the country of EBRT to enable a long-term follow-up\n* Signed informed consent\u002Fassent\n\nExclusion Criteria:\n\n* Patients with poor prognosis (e.g. diffuse pontine glioma or high grade glioma)\n* Prior external or internal radiation therapy;\n* Protected adults (persons under curatorship, tutorship \u002F individuals under guardianship by court order, persons deprived of their liberty)\n* Adult\u002Fparent(s)\u002Flegal representative(s) who cannot read or understand the informed consent in the applicable language(s) in the country of EBRT","22 Years",{"count":201,"type":23},2670,"20 Years","The goal of the HARMONIC-RT study is to evaluate late health and social outcomes of contemporary techniques of external beam radiotherapy in paediatric patients, based on the setting-up of a European, long-term registry complemented by a biobank.",[205],"Neoplasms",[207,208,209,210,211,212,213,214,215,216,217,218,219,220,221],"Radiotherapy","Oncology","Paediatrics","Late toxicities","Radiation-induced neoplasms","Radiation-induced vascular damages","Radiation-induced cardiac damages","Radiation-induced endocrine damages","Quality of life","Social outcomes","External beam radiotherapy","Photon therapy","Proton therapy","Cohort","Registry",{"date":90,"type":36},{"date":224,"type":36},"2021-01-11",{"date":226,"type":23},"2042-01-02",{"name":42,"class":43},5,{"id":230,"slug":231,"hasResults":12,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":12,"sex":19,"minAge":4,"maxAge":237,"enrollmentInfo":238,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":240,"conditions":241,"keywords":246,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":228},"100570778","prenatal-maternal-mental-health-and-neurodevelopment-in-congenital-heart-disease-100570778","NCT06711666","Prenatal Maternal Mental Health and Neurodevelopment in Congenital Heart Disease","Prenatal Maternal Mental Health and Neurodevelopment in Children With an Antenatal Diagnosis of Congenital Heart Disease: The Neuro-Moms CHD Study","Neuro-Moms","Inclusion Criteria for the mother of a child diagnosed with CHD:\n\n1. Age at least 18 years old\n2. Expecting women\n3. Having received a diagnosis of foetal critical cyanotic CHD (i.e., CHD physiology that can compromise blood oxygenation after birth). This type of CHDs corresponds to the highest level of neurological risk as reported by the American Heart Association guidelines(1).\n4. Pregnancy of at least 28 weeks of gestation (third trimester) and up to the 38 weeks of gestation at the time of enrolment and prenatal visit for the study.\n5. Medical maternal and paediatric cardiology follow-up in one of the investigating hospitals (Montpellier, Necker Children's Hospital in Paris and Bordeaux).\n6. A delay of a minimum of 4 weeks between the initial diagnosis of foetal congenital heart disease.\n7. Social security affiliation in France.\n\nInclusion criteria for the father or co-parent:\n\n1. Co-parent of an expecting woman participating in the study\n2. Age at least 18 years old\n3. Social security affiliation in France.\n\nInclusion criteria for the child diagnosed with congenital heart disease:\n\n1. Child with a prenatal diagnosis of isolated complex congenital heart disease, born to a mother already participating in the study\n2. Written consent from both parents\n3. Social security affiliation in France.\n\nNon-inclusion Criteria for mothers:\n\n1. Patient refusal to participate\n2. Participants (i.e., expecting women) who express a wish for medical termination of pregnancy\n3. Diagnosis of a complex CHD associated with another foetal comorbidity with a clinically recognized impact on neurodevelopment (e.g., genetic syndromes such as trisomies, poly-malformation syndromes).\n4. Participants who are not able to understand the instructions and\u002For complete the self-reports\n5. Expecting women who currently have a major psychiatric condition (e.g., untreated major depression, severe anxiety disorders, psychotic disorders) with or without treatment, at the time of the cardiology consultation or at the time of the first psychological evaluation. Patients who will be excluded due to these conditions will be referred for perinatal psychiatric consultation.\n6. Persons under legal or judicial guardianship.\n\nNon-inclusion Criteria for fathers or co-parents:\n\n1. Patient refusal to participate\n2. Participants with a severe psychiatric disorder (severe depression, psychotic disorders) with or without treatment\n3. Persons under legal or judicial guardianship.\n\nExclusion Criteria for the mother of a child diagnosed with CHD:\n\n1\\. The child has not undergone surgery within 60 days of birth.\n\nExclusion Criteria for children with CHD:\n\n1\\. Genetic anomalies, brain malformations that may render difficult the neurodevelopmental assessment.","50 Years",{"count":239,"type":23},174,"Congenital heart disease (CHD) is the leading cause of congenital malformations, representing 1% of live births. Progress in surgical care have led to the dramatic increase in the population of children and adults living with heart disease. As survival is no longer a concern, long-term outcomes have become the major public health issue. Prenatal diagnosis of CHD requiring open-heart surgery can be a traumatic event for expecting mothers and fathers. In the general population, maternal mental health distress is associated with fetal disturbances in the hypothalamic-adrenal-pituitary system axis, restricted intrauterine growth and adverse outcomes in the offspring. It is unknown whether prenatal maternal psychological distress have an impact on neurodevelopmental outcomes in CHD. Our national study seeks to (1) characterize the impact of prenatal maternal psychological distress on neurodevelopmental outcomes at age 1 for children with CHD who undergo neonatal open-heart surgery; (2) investigate the sociodemographic and medical determinants associated with prenatal maternal mental health of women carrying a foetus diagnosed with complex CHD; (3) explore the mediating role of prenatal risk factors (i.e., sociodemographic, medical and maternal coping mechanisms) in the association of prenatal maternal mental health (i.e., distress, anxiety and depression) and neurodevelopment in children with CHD; and (4) explore the impact of paternal or the co-parent's mental health impact on neurodevelopmental outcomes at age 1 in children with CHD. This study is a non-interventional, prospective, and longitudinal study of prenatal maternal mental health and subsequent child's neurodevelopmental and behavioural outcomes. It includes a follow-up period from the 3rd trimester of pregnancy until the child's first year of life. It will include children with a prenatally diagnosed heart defect requiring open-heart surgery within the first weeks of life. Understanding and preventing the neurodevelopmental sequelae of heart disease diagnosed in-utero is a public health priority.",[242,243,244,245],"Congenital Heart Disease","Cyanotic Congenital Heart Disease","d-Transposition of the Great Arteries","Hypoplastic Left Heart Syndrome",[247,248,249,250,251],"psychological stress","Maternal prenatal mental health","Neurodevelopment","Cyanotic congenital heart disease","Prenatal diagnosis","2026-07-29",{"date":113,"type":36},{"date":255,"type":36},"2025-06-27",{"date":257,"type":23},"2029-02",{"name":42,"class":43},{"id":260,"slug":261,"hasResults":12,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":12,"sex":19,"minAge":4,"maxAge":103,"enrollmentInfo":267,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":269,"conditions":270,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":272,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":278},"100180217","french-childhood-cancer-survivor-study-100180217","NCT01620372","French Childhood Cancer Survivor Study","Constitution d'Une Cohorte Nationale rétrospective de Survivants d'un Cancer Solide de l'Enfant diagnostiqué Avant 2000","FCCSS","Inclusion Criteria:\n\n* All types of solid childhood cancer in France\n* Age at diagnosis: Below age 19\n* Period of diagnosis: between 1st January 1942 and 31st December 1999\n* Complete identification (first name, last name, date of birth and place of birth)\n\nExclusion Criteria:\n\n* Leukaemia cases",{"count":268,"type":23},18000,"The FCCSS is a multicentric national large-scale collaborative population-based study of children treated for a solid tumor before 2000 in France and before the age of 19 years.\n\nThe study is concerned by improving knowledge about the long-term effects caused by cancer and its treatments including adverse health and social outcomes.\n\nThe main reason of the FCCSS is to estimate the risk of adverse health and social outcomes that may occur after a cancer treatment and to prevent them by providing adapted follow-up care.\n\nThe cohort will be followed for up to 20 years from 2011.",[271],"Childhood Solid Tumor",{"date":113,"type":36},{"date":274,"type":36},"2011-11-15",{"date":276,"type":23},"2031-11-15",{"name":42,"class":43},36,{"id":280,"slug":281,"hasResults":12,"nctId":282,"briefTitle":283,"officialTitle":283,"acronym":284,"eligibilityCriteria":285,"healthyVolunteers":18,"sex":19,"minAge":4,"maxAge":4,"enrollmentInfo":286,"targetDuration":4,"studyType":56,"phases":288,"briefSummary":289,"conditions":290,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":69},"100383427","molecular-characterization-for-understanding-biliary-atresia-100383427","NCT04272515","Molecular Characterization for Understanding Biliary Atresia","CAVB","Inclusion Criteria:\n\n* confirmed diagnosis of biliary atresia in patients\n* parents of BA patients\n\nExclusion Criteria:\n\n* no",{"count":287,"type":23},100,[58],"Although considered a rare disease, Biliary Atresia (BA) is the leading cause of neonatal cholestasis and liver transplantation in children. Little is known about the molecular mechanisms that drive BA. The purpose of this study is to collect the fluid samples, explanted liver tissue samples and dermal biopsy samples to enable investigators to perform the genetic and molecular analyses that might point to the gene(s) and cellular pathway involved in etiology of BA disease.",[291],"Biliary Atresia","2026-07-21",{"date":294,"type":36},"2026-07-22",{"date":296,"type":36},"2021-02-07",{"date":298,"type":23},"2032-02-07",{"name":42,"class":43},{"id":301,"slug":302,"hasResults":12,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":4,"eligibilityCriteria":306,"healthyVolunteers":12,"sex":19,"minAge":103,"maxAge":307,"enrollmentInfo":308,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":310,"conditions":311,"keywords":316,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":44},"100470053","metabolic-and-infectious-diseases-in-la-runion-the-reunion-population-based-study-100470053","NCT05400824","Metabolic and Infectious Diseases in La Réunion (the REUNION Population-based Study)","Pathologies métaboliques et Infectieuses en Population générale à La Réunion : étude REUNION","Inclusion Criteria:\n\n* 18-67 years\n* given consent for genetic analysis,\n* written consent for participating in the study\n\nExclusion Criteria:\n\n* judicial protection or guardianship","67 Years",{"count":309,"type":23},2000,"The aim of the present study is to determine the prevalence of cardiometabolic and infectious disease in La Reunion (french oversea department and region of France).\n\nKnown or suspected risk factor for these diseases will also be assessed, such as microbiota, cognitive impairement, social inequalities, and genetics.",[312,313,314,315],"Infectious Disease","Cardiovascular Diseases","General Population","Metabolic Disease",[317,318,319,320,321,322,323,324,325],"epidemiology","risk factors","prevalence","cognitive impairment","dengue","hypertension","dyslipidemia","social inequalities","autonomous nervous system","2026-07-09",{"date":328,"type":36},"2026-07-10",{"date":330,"type":36},"2022-05-01",{"date":332,"type":23},"2027-12",{"name":42,"class":43},{"id":335,"slug":336,"hasResults":12,"nctId":337,"briefTitle":338,"officialTitle":338,"acronym":339,"eligibilityCriteria":340,"healthyVolunteers":12,"sex":19,"minAge":341,"maxAge":342,"enrollmentInfo":343,"targetDuration":4,"studyType":56,"phases":345,"briefSummary":346,"conditions":347,"keywords":351,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":44},"100501241","investigation-of-alzheimers-predictors-in-subjective-memory-complainers---extension-study-100501241","NCT05806697","Investigation of AlzHeimer's Predictors in Subjective Memory Complainers - Extension Study","INSIGHT-2","Inclusion Criteria:\n\n* Subjects that previously participated in the INSIGHT cohort\n* Aged 70 to 95 years old\n* Having signed an informed consent\n* Willing to and able undergo a baseline PET amyloid imaging\n* Affiliating to the French health-care system\n* Having an identified informant who has sufficient contact with the participant and has to be able to provide accurate information, at least by phone, about the participants' cognitive and functional abilities.\n\nExclusion Criteria:\n\n* Clinical Dementia Rating ≥1 at screening\u002Fbaseline visit only\n* Fulfilling research diagnostic criteria for any type of dementia-related disorder at screening visit (clinical AD, Dementia with Lewy Bodies \\[DLB\\], fronto-temporal dementia \\[FTD\\], vascular dementia, chronic traumatic encephalopathy \\[CTE\\], Limbic-predominant Age-related TDP-43 Encephalopathy \\[LATE\\], Primary age-related tauopathy \\[PART)\n* Presence of any medical condition associated with a long-term risk of cognitive impairment or dementia including Parkinson's disease, brain tumor, subdural hematoma, vascular malformations, territorial stroke (excluding smaller watershed strokes), chronic hydrocephalus, traumatic brain injury with neurological sequelae, active alcohol\u002Fdrug abuse, major depressive disorder, schizophrenia and bipolar disorder\n* Current serious or unstable illnesses (including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic or hematologic disease) that might make the subject's participation in an investigational trial unsafe\n* Any contraindications for MRI\u002F PET scan procedure (claustrophobia, ferromagnetic object in the body), to FDG or to 18F-Florbetapir (Amyvid®).\n* Hypersensitivity to the active substance or to any of the excipients of 18F-Florbetapir (Amyvid®).\n* Participation in any clinical trial of an investigational product in the last 30 days before the screening (during all study duration co-inclusion in other clinical trial of an investigational product or observational research \\[biomarker cohort e.g.\\] will be possible but the information would need to be recorded).\n* Unable to comply with protocol requirements in the opinion of the investigator\n* Being under guardianship (safeguard of justice, curatorship or guardianship)\n* Residence in skilled nursing facility, including nursing homes (EHPAD).","70 Years","95 Years",{"count":344,"type":23},240,[58],"A regional, single-center, prospective, observational academic cohort will follow subjects who previously participated in the INSIGHT study and who agree an extension of their follow-up in the INSIGHT-2 research for additional 5-6 years. An annual multimodal evaluation (cognitive, oculomotor, biological and neuroimaging) will be proposed in order to describe the natural history of preclinical Alzheimer's disease (AD). The primary endpoint is the conversion to the symptomatic stage in subjects at risk, identified by positive amyloid staining (A+) on florbetapir positron emission tomography (PET) imaging. The size of the cohort is estimated to around 240 participants (61 A+ subjects) among the 318 participants included in the main cohort (88 A+ subjects). The follow-up in the INSIGHT-2 cohort will be lightened compared to that of the main cohort with an annual frequency of visits rather than a six-monthly one.",[348,349,350],"Alzheimer Disease","Memory Complaint","Memory Disorders",[352,353,354,355,356,357],"risks factors","brain amyloid load","neurosciences","neurology","memory complaint","memory disorders","2026-07-06",{"date":360,"type":36},"2026-07-07",{"date":362,"type":36},"2023-04-14",{"date":364,"type":23},"2030-10-09",{"name":42,"class":43},{"id":367,"slug":368,"hasResults":12,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":372,"eligibilityCriteria":373,"healthyVolunteers":12,"sex":19,"minAge":103,"maxAge":4,"enrollmentInfo":374,"targetDuration":4,"studyType":56,"phases":376,"briefSummary":377,"conditions":378,"keywords":380,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":69},"100493047","mrs-of-glioma-genomics-100493047","NCT05700071","MRS of Glioma Genomics","Magnetic Resonance Spectroscopy Markers of Glioma Genomics","GLIOMRS","Inclusion Criteria :\n\n* Affiliations to a social security scheme (as a beneficiary or a person entitled to benefits)\n* Obtainig written, informed consent\n* One of the following two situations\n\n  * Group 1 : Probable grade II\u002FIII\u002FIV glioma, for which excision is scheduled.\n  * Group 2 : Histologically confirmed grade II or III glioma with known IDH1\u002FIDH2 status, which has received no treatment other than surgery and is due to undergo therapy other than surgery.\n* Presence of measurable tumor residue (\\>2 cm in diameter on FLAIR imaging)\n* Karnofsky Index \\> 60\n* Effective contraception throughout the study, supplemented by a negative pregnancy test for women of childbearing age.\n\nExclusion Criteria:\n\n• Containdications to MRI : Pacemaker or neural stimulators, intraocular or intracerebral metallic foreign bodies, cochlear implant, heart valve or metallic surgical arterial devices that are not MRI ompatible, metallic devices susceptible to concentrating radio-frequency pulses, claustrophobia\n\n* Pregnant or breastfeeding women\n* Regulatory criteria :\n\nPregnant women, women in labor, breastfeeding women ; Failure to sign the consent form or paticipant refusal ; Legal protection measures (guardianship, curatorship, judicial protection) ; Participation in another research study that does not allow for compliance with the exclusion period between the two studies ; Individuals not covered by a health insurance scheme.",{"count":375,"type":23},110,[58],"In France, about 5000 new people with a primary malignant brain tumor are diagnosed each year. The most common primary tumors are gliomas, originating from glial cells (astrocytomas and oligodendrogliomas). Low-grade gliomas are mildly aggressive, but they often evolve into a more malignant form.\n\nMutations in the genes encoding isocitrate dehydrogenase (IDH) are found in about 80% of low-grade gliomas and are associated with a favorable prognosis. Remarkably, IDH-mutated gliomas are characterized by a specific cellular metabolism causing the accumulation of D-2-hydroxyglutarate (2HG) in tumor cells. 2HG can be detected in vivo using 1H magnetic resonance spectroscopy (MRS) and is recognized as a unique, noninvasive biomarker of IDH-mutated gliomas. Noninvasive detection of IDH mutations via 2HG MRS represents a crucial step for decision-making and patient care.\n\nA subset of IDH-mutated tumors also presents a complete deletion of 1p and 19q chromosome arms (1p\u002F19q codeletion). The 1p\u002F19q codeletion is specifically linked to the oligodendroglial histologic subtype and it has been associated with a better patient outcome. However, the biological effects of this genetic alteration are still unclear and in vivo markers are lacking. Recently, we reported the first in vivo detection of the cystathionine molecule in human brain gliomas using MRS and explored the association between cystathionine accumulation and 1p\u002F19q codeletion in gliomas.\n\nIn this project, the investigation team will combine cutting edge MRI and MRS techniques for metabolic and microstructural characterization of brain tumors with the aim of providing novel reliable noninvasive biomarkers of tumor genetic subtypes. These methods will enable noninvasive identification of IDH-mutated gliomas and, potentially, 1p\u002F19q codeleted gliomas. In addition, the researchers will investigate the utility of 2HG, cystathionine and MRI microstructural markers to monitor tumor response to anti-cancer treatments and tumor progression.\n\nThe outputs of this project, altogether, may open new avenues to a better understanding of the pathophysiological mechanisms of oncogenesis and the design of new treatments for gliomas.",[379],"Glioma",[381,382,383,384,385,386,387],"Gliomas","Isocitrate dehydrogenase","1p19q codeletion","MR Spectroscopy","MRI","Diagnosis","Treatment monitoring",{"date":389,"type":36},"2026-07-08",{"date":391,"type":36},"2023-03-06",{"date":393,"type":23},"2028-03-02",{"name":42,"class":43},{"id":396,"slug":397,"hasResults":12,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":401,"eligibilityCriteria":402,"healthyVolunteers":18,"sex":19,"minAge":103,"maxAge":341,"enrollmentInfo":403,"targetDuration":4,"studyType":56,"phases":404,"briefSummary":405,"conditions":406,"keywords":408,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":417,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":69},"100184917","subthalamic-nucleus-akinesia-and-parkinsons-disease-100184917","NCT01682668","Subthalamic Nucleus, Akinesia and Parkinson's Disease","Role of the Subthalamic Nucleus in the Control of Movement: Physiopathology of Akinesia in Parkinson's Disease.","GB-MOV","Inclusion criteria for patients who will be operated\n\n1. Diagnosis of idiopathic Parkinson's disease (according to the criteria of the United Kingdom Parkinson's Disease Society Brain Bank)\n2. Age between 18 and 70;\n3. Motor complications in the form of fluctuations in motor state or dyskinesias induced by dopaminergic therapy, despite medical treatment optimum;\n4. Other medical conditions that are stable or do not interfere with the procedure proposed;\n5. Excellent responsiveness to levodopa (UPDRS motor score improvement greater than 50% in the acute levodopa test)\n6. Brain MRI without abnormality\n7. Normality of biological examinations\n8. Person who has voluntarily and informedly agreed to participate in the study (signature of a written consent)\n9. Patient with social health insurance\n\nCriteria for non-inclusion of Parkinsonian patients who will be operated\n\n1. Contraindication to examinations necessary for inclusion\n2. Evolutionary psychiatric pathology;\n3. Dementia(MMS\\\u003C24\u002F30);\n4. Patients with a medical condition that makes surgery dangerous neuro-surgical;\n5. Bleeding-promoting diseases and laboratory test abnormalities clotting;\n6. Existence of contraindications to MRI (cardiac or neural pacemaker, clips ferromagnetic surgeries, implants and metal objects, foreign bodies intraocular, pregnancy, claustrophobia).\n7. Taking drugs interfering with coagulation for 1 month before intervention.\n8. Persons under guardianship, curatorship or any other administrative or judicial measure deprivation of rights and liberty\n\nSelection criteria for non-operated patients\n\n1. Diagnosis of idiopathic Parkinson's disease (according to the criteria of the United Kingdom Parkinson's Disease Society Brain Bank);\n2. Age between 18 and 70;\n3. Other medical conditions that are stable or do not interfere with the proposed protocol;\n4. Presence of axial signs (gait and\u002For balance disorders) no improved by antiparkinsonian treatment\n5. Brain MRI without notable abnormality\n6. Normality of biological examinations\n7. Person who has voluntarily and informedly agreed to participate in the study (signature of a written consent)\n8. Patient with social health insurance\n\nCriteria for non-inclusion of non-operated patients\n\n1. Contraindication to examinations necessary for inclusion\n2. Progressive psychiatric pathology;\n3. Dementia (MMS\\\u003C24\u002F30);\n4. Existence of contraindications to MRI (cardiac or neural pacemaker, clips ferromagnetic surgeries, implants and metal objects, foreign bodies intraocular, pregnancy, claustrophobia).\n5. Persons under guardianship, curatorship or any other administrative or judicial measuredeprivation of rights and liberty\n\nInclusion criteria for group 3 patients (already operated)\n\n1. Diagnosis of idiopathic Parkinson's disease (according to the criteria of the United Kingdom Parkinson's Disease Society Brain Bank);\n2. Bilateral deep brain stimulation of the subthalamic nucleus for more than 1 year\n3. Age between 18 and 70;\n4. Person who has voluntarily and informedly agreed to participate in the study (signature of a written consent)\n5. Patient with social health insurance\n\nCriteria for non-inclusion of Parkinsonian patients (already operated)\n\n1. Contraindication to examinations necessary for inclusion\n2. Evolutionary psychiatric pathology;\n3. Dementia(MMS\\\u003C24\u002F30);\n4. Persons under guardianship, curatorship or any other administrative or judicial measure deprivation of rights and liberty\n\nInclusion criteria for healthy subjects\n\n1. Age between 18 and 70 years old\n2. Normal neurological examination\n3. Person who voluntarily and informedly agreed to participate in the study (signature of a written consent)\n4. Patient with social health insurance\n\nCriteria for non-inclusion of healthy subjects\n\n1. Persons under guardianship, curatorship or any other administrative or judicial measure of deprivation of rights and freedom\n2. Existence of neurological, orthopedic or psychiatric history\n3. Existence of contraindications to MRI (cardiac or neural pacemaker, ferromagnetic surgical clips, implants and metallic objects, foreign bodies intraocular, pregnancy, claustrophobia).",{"count":150,"type":23},[58],"This program aims to understand the role of the subthalamic nucleus in the control of the movement in healthy humans and patients with Parkinson's disease, how the STN dysfunction contributes to akinesia and how the STN stimulation improves motor signs in PD patients .",[407],"Parkinson's Disease",[409,410,411,412,413,414,415,416],"parkinson's disease","subthalamic nucleus","akinesia","gait initiation","neuronal activity","before STN stimulation","with STN stimulation","functional MRI",{"date":360,"type":36},{"date":419,"type":36},"2013-02",{"date":421,"type":23},"2026-08",{"name":42,"class":43},{"id":424,"slug":425,"hasResults":12,"nctId":426,"briefTitle":427,"officialTitle":427,"acronym":428,"eligibilityCriteria":429,"healthyVolunteers":18,"sex":19,"minAge":103,"maxAge":430,"enrollmentInfo":431,"targetDuration":4,"studyType":56,"phases":433,"briefSummary":434,"conditions":435,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":443,"locationsCount":44},"100609350","identification-of-early-markers-for-als-100609350","NCT07213440","Identification of Early Markers for ALS","PremodiALS","Inclusion Criteria:\n\nFIRST GROUP: Premotor gene mutation carriers (PGMC):\n\n* 18-90 years of age\n* Provision of a written informed consent\n* Affiliation with a social security scheme or beneficiary of such a scheme\n* Diagnosed by a clinically certified laboratory with a disease- causing mutation in a known ALS gene by predictive genetic testing\n* No symptoms of motor neuron disease explainable otherwise than by mutation in a known ALS gene\n\nSECOND GROUP: Control subjects to premotor gene mutation carriers (CTR):\n\n* 18-90 years of age\n* Provision of a written informed consent\n* Affiliation with a social security scheme or beneficiary of such a scheme\n* No known genetic mutation and no known ALS disease in close family\n* No diagnosed motor-neuron disease\n\nTHIRD GROUP: ALS (EALS) \u002F ALS mimics (MIM)\n\n* 18-90 years of age\n* provision of a written informed consent\n* affiliation with a social security scheme or beneficiary of such a scheme\n* Patients with pure motor symptom or early ALS (EALS) or ALS mimics (MIM)\n\nEALS are patients with pure motor symptom \u002F early motor symptoms of ALS, including those, where the diagnosis of ALS can already be made. These may be patients who meet the following criteria:\n\nAccording to El Escorial criteria : patients who can be classified as possible ALS or those who show upper motor neuron (UMN) signs only or lower motor neuron (LMN) signs only, so that classification as possible ALS is also not possible. Symptoms should not persist for more than 12 months.\n\nAccording to Gold Coast criteria: Patients who do not fulfill the criterion of temporal progression or patients who only show UMN signs or only LMN signs in one region and thus do not fulfill the diagnostic criteria of ALS.\n\nExclusion Criteria:\n\n* Inability to express consent to the study\n* Persons subject to a judicial safeguard measure, under guardianship or curatorship.\n* Linguistic incapacity or psychic refusal to read the information.\n* Pregnant women\n* Foreseen inability to attend scheduled visits\n* Persons refusing to take one of the following samples: Acquisition of blood samples, Acquisition of tear fluid samples, Acquisition of urine sample","90 Years",{"count":432,"type":23},60,[58],"Although several molecules have been proposed as biomarker candidates, a clinically established signature for an early or even premotor diagnosis of ALS is not available. Due to the already advanced, disease stage at the time of diagnosis as well as rapid disease progression, an early diagnosis is mandatory for efficacious disease-modifying therapies.\n\nIn this project, the investigators will develop a clinical molecular fingerprint of PGMC that will provide insight into the molecular pathogenesis of ALS and allow earlier diagnosis.",[436],"Amyotrophic Lateral Sclerosis (ALS)","2026-07-03",{"date":360,"type":36},{"date":440,"type":36},"2024-09-30",{"date":442,"type":23},"2027-04",{"name":42,"class":43},{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":448,"acronym":449,"eligibilityCriteria":450,"healthyVolunteers":18,"sex":19,"minAge":103,"maxAge":451,"enrollmentInfo":452,"targetDuration":4,"studyType":56,"phases":454,"briefSummary":455,"conditions":456,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":462,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":44},"100598420","study-of-the-correlation-between-cortical-excitability-and-cytoarchitectonics-of-prefrontal-cortex-in-healthy-adult-participants-using-transcranial-magnetic-stimulation-coupled-to-eeg-and-high-field-mri-100598420","NCT07071259","Study of the Correlation Between Cortical Excitability and Cytoarchitectonics of Prefrontal Cortex in Healthy Adult Participants, Using Transcranial Magnetic Stimulation Coupled to EEG and High-field MRI","FrontalProbe","Inclusion Criteria:\n\n* People aged 18 to 35\n* People affiliated with a social security scheme or beneficiary of such a scheme\n* People who have signed the informed consent\n* Right-handed people\n* People with a body mass index between 18 and 26\n* People able to abstain from alcohol for 24 hours prior to the experiment\n* People able to remain perfectly still for 15 minutes straight, and able to have reduced mobility for 3 hours\n* People able to of not using narcotics (marijuana, cocaine, ecstasy, MDMA, ketamine, etc.) during the 15 days preceeding the experiment.\n* Conducting a pregnancy test before inclusion for women of childbearing age and when the research is conducted over a long period, at a frequency adapted to the gaze of the research acts\n* Effective contraception for women of childbearing potential\n\nExclusion Criteria:\n\n* Pregnant, parturient, or breastfeeding\n* Protected adults\n* Minors\n* People staying in a healthcare or social institution\n* People in an emergency situation\n* People deprived of their liberty\n* People with the usual contraindications to MRI\n\n  * Ferromagnetic surgical clips, ocular implants, metallic foreign bodies intraocularly or in the nervous system, implants or metallic objects susceptible to concentrate the radio frequency field, cochlear implants, brain stimulator or cardiac pacemaker, presence of a craniotomy scar, agitation\n  * Claustrophobia\n  * Large, black tattoo close to the orofacial area\n* People not wishing to be informed of abnormalities discovered at the MRI\n* People with a history of epilepsy or suffering from epilepsy\n* Individuals whose parents, children, siblings, or parents have a history of epilepsy\n* People with known neurological and\u002For psychiatric disorders with past and\u002For current medical treatment, or drug addiction\n* Staff with a hierarchical link to the investigators","35 Years",{"count":453,"type":23},34,[58],"Repeated transcranial magnetic stimulation (rTMS) is mainly used to treat mood disorders by addressing differences in brain function, particularly in the dorsolateral prefrontal cortex (DLPFC), which affects emotions and executive functions. The therapy aims to enhance the left DLPFC or suppress the right. It has been approved for severe major depression in several countries (Canada and Israel since 2002, USA since 2008) and is in the process of being validated in Europe but is not yet reimbursed in France. due to variable results from one study to another and lack of standardization issues.\n\nIn a previous study, by recording electroencephalographic (EEG) rhythms before and after rTMS treatment of the DLPFC, the investigators showed on a small cohort of patients (n=17) with major or bipolar depression, that the responder patients showed higher EEG theta rhythms in the DLPFC but also and especially in parietal regions. This suggests that the DLPFC is part of the fronto-parietal central executive network (CEN), which is important for working memory and cognitive control. The CEN is not well connected in severe resistant depression, possibly leading to negative emotional bias. The rTMS cure of DLPFC can be interpreted as improving depressive symptoms through the normalization of the CEN by increasing DLPFC excitability and its downward connectivity. However experimental and clinical evidence for this mechanism, among others, is still to be demonstrated, and remission rates of rTMS from DLPFC in drug-resistant depression are still low (20-40%).\n\nTo improve these response rates to rTMS in DLPFC, it is essential to continue research aimed at improving clinical practices through a better knowledge of the functional neuroanatomy and mechanisms of action of rTMS. This will require the definition of biomarkers allowing in particular to better target the DLPFC, this structure beeing indeed relatively poorly defined on the neuroanatomical level (large portion of the medial frontal gyrus). To this end, the investigators have set up a collaborative research program with Dr. Corey Keller, psychiatrist at Stanford University USA, which was jointly funded in 2022 by the Agence Nationale pour la Recherche (ANR) and the National Institute of Health (NIH) - FrontalProbe project \"Probing the dorsolateral prefrontal cortex and central executive network for improving neuromodulation in depression\". The ultimate aim of this project is to develop and test different strategies for targeting the DLPFC in the rTMS treatment of pharmaco-resistant depressive patients, following the fundamental neuroanatomical and pathophysiological hypothesis that patients will respond better to therapy if their CEN network is better modulated. This clinical trial will take place in Stanford, USA, in the years 2025-2026. Previously, the investigators are working on the development of methodological strategies aimed at preferentially activating, in a personalized way, the part of the DLPFC that projects onto the PPC. This is the subject of the present protocol, which aims to identify this subpart of the DLPFC to be targeted as a priority for modulating the CEN, through neuroanatomical measurements with high-field MRI and cortical excitability by TMS-EEG in healthy subjects. To this end, the investigators will use a small cohort of healthy subjects who will have one multimodal MRI acquisition session of at 7T and one TMS-EEG session. The 7T MRI data, acquired at the Centre de Résonance Magnétique en Biologie et Médecine (CRMBM), will be used to obtain anatomical markers of the DLPFC. TMS-EEG data, acquired at the Institut de Neurosciences de Systèmes (INS), will be used for cortical excitability measurements of the DLPFC and its projection sites, notably the PPC. At this stage, no data exchange is planned with our American partners.\n\nFirstly, the processing of MRI data will include segmentation of gray and white matter, reconstruction of the cortical surface and estimation of the different cortical layers, mainly by monitoring variations in the T1 parameter along the cortical mantle. Other MRI parameters will also be acquired to maximize the specificity of the segmentation of the DLPFC into sub-regions, firstly by identifying the part of the DLPFC that connects preferentially to the PPC using the reconstruction of fiber bundles from diffusion MRI and functional resting MRI. Secondly, during TMS-EEG acquisitions, participants will be stimulated in 3 sub-regions of the DLPFC. For each target, the analyses of the EEG data will focus on quantifying connectivity with the PPC as well as their spectral signature, which is possibly an indirect reflection of the neuronal composition of the stimulated regions.\n\nCorrelation of 7T MRI and TMS-EEG data will help set optimal DLPFC targeting criteria for PPC activation. The aim is to create an MRI-based targeting procedure for clinical practice. In this sense, TMS-EEG will serve as validation of MRI markers.",[457,458,385,459,460,461],"Healthy Participants","Magnetic Stimulation","EEG","Dorsolateral Prefrontal Cortex","rTMS Stimulation",{"date":360,"type":36},{"date":464,"type":36},"2026-06-29",{"date":466,"type":23},"2028-04",{"name":42,"class":43},{"id":469,"slug":470,"hasResults":12,"nctId":471,"briefTitle":472,"officialTitle":472,"acronym":473,"eligibilityCriteria":474,"healthyVolunteers":18,"sex":19,"minAge":103,"maxAge":4,"enrollmentInfo":475,"targetDuration":4,"studyType":56,"phases":476,"briefSummary":477,"conditions":478,"keywords":481,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":483,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":488,"locationsCount":69},"100597840","identification-of-cellular-biomarkers-of-rare-eye-diseases-in-adults-100597840","NCT07063719","Identification of Cellular Biomarkers of Rare Eye Diseases in Adults","REVIBIO","Inclusion Criteria:\n\nPatient group:\n\n* Women and men with age equal or higher than 18 years (patients planning to conceive may be included in the study)\n* Willingness and ability to read and understand the informed consent.\n* Diagnosis (including genotype, if needed) of REDs.\n* Affiliation with a social security scheme or beneficiary of such a scheme.\n\nRED 1 - AAK Diagnosis criteria\n\n* Compatible slit lamp examination (iris\u002Fpupillary abnormalities, with or without corneal opacification, vascularization, cataract, glaucoma). with or without:\n* Foveal hypoplasia and optic disc malformations as detected through fundus examination or OCT tomography\n* Compatible anterior segment OCT or high-frequency ultrasound biomicroscopy (UBM)\n* Positive genetic testing\n\nRED 2 - NK Diagnosis criteria\n\n* Compatible history and slit lamp findings of one of the three stages of the Mackie classification (I - punctate keratopathy; II - persistent epithelial defect; III - stromal involvement)\n* Reduced\u002Fabsent corneal sensitivity\n* Exclusion of infectious or toxic etiologies with or without:\n* confocal microscopy findings\n\nRED 3 - LSCD Diagnosis criteria\n\n* Compatible history and slit lamp examination (e.g. corneal conjunctivalization with persistent epithelial defects, loss of limbal anatomy or irregular staining with fluorescein) with or without:\n* confocal microscopy findings\n\nRED 4 - OCP Diagnosis criteria\n\n* Compatible slit lamp examination\n* Exclusion of infectious or toxic etiologies with or without:\n* conjunctival \u002Foral biopsy with characteristic mucous pemphigoid findings\n\nRED 5 - OC GVHD Diagnosis criteria • Compatible history and slit lamp examination consistent with one of 4 grades of ocular GVHD (1 - conjunctival hyperemia, 2 - fibrovascular changes \\\u003C25% of palpebral conjunctiva, 3 - fibrovascular changes \\>25%, 4 - \\>75% or cicatricial entropion)\n\nRED 6 - EEC Diagnosis criteria\n\n* Compatible slit lamp examination\n* Compatible systemic findings with or without:\n* Positive genetic testing\n\nRED 7- CNV Diagnosis criteria\n\n* Compatible slit lamp examination of corneal stromal neovascularization (1-4 quadrants)\n* Exclusion of infectious or toxic etiologies with or without:\n* confocal microscopy findings\n\nControl group:\n\n* Women and men with age equal or higher than 18 years (patients planning to conceive may be included in the study).\n* Willingness and ability to read and understand the informed consent.\n* Non-diagnosis of REDs.\n* Affiliation with a social security scheme of beneficiary of such a scheme.\n\nExclusion Criteria:\n\nPatient group:\n\n* Pregnancy, breastfeeding (in case any stress was caused to the woman by the biological sampling).\n* Descemetocele\u002Fimpending corneal perforation.\n* Recent (less than 3 months) ocular surgery.\n* Recent (less than 1 month) change in topical medications type and frequency of the ocular pathology.\n* Persons subject to a legal protection measure (under guardianship, curatorship or safeguard of justice)\n\nControl group:\n\n* Pregnancy, breastfeeding.\n* Active ocular infection.\n* Descemetocele\u002Fimpending corneal perforation.\n* Recent (less than 3 months) ocular surgery.\n* Recent (less than 1 month) change in topical medications type and frequency of the ocular pathology.\n* Persons subject to a legal protection measure. (under guardianship, curatorship or safeguard of justice)",{"count":375,"type":23},[58],"The cornea is the outermost transparent 'window' of the eye allowing light to enter and serving as the first-line immune and mechanical barrier. It is a complex avascular tissue composed of cells, stem cells, nerves, and collagen layers organized in an exquisite manner to maintain its transparency and self-healing capacity. This delicately balanced interplay of corneal elements is disrupted in rare diseases of the cornea, resulting in non-healing wounds, corneal ulceration, inflammation, new vessel ingrowth (neovascularization), defective innervation, scarring, oedema and loss of transparency. For many Rare Eye Diseases (REDs), drug development has been relatively unsuccessful, delivering few to no new therapies. Current management is often prohibitively expensive, has low efficacy and leads to debilitating side effects. The RESTORE VISION project (https:\u002F\u002Frestorevision-project.eu\u002F) aims to improve eye health by using cutting-edge models for each rare disease to test novel and repurposed compounds (9 in total) and determine drug mechanisms of action, formulating compounds as safe eye drop suspensions, and performing several first-in-human trials of novel therapies. Thes drugs have solid preliminary data showing beneficial effects in restoring the cell physiology, immune, avascular, neural and signaling environment in the cornea.\n\nThe current clinical study is part of Work package 2 within the RESTORE VISION EU grant agreement (''Validation of human drug targets of repurposed drugs and novel therapies'') and aims to ascertain the expression levels of genes and proteins and investigate pathways of interest in human tissue and fluid samples of REDs, that are targeted by the proposed experimental\u002Frepurposed substances. Therapeutic target gene and\u002For protein expression will be verified in human blood, tears and conjunctival cells collected from 7 RED patient groups. The RESTORE VISION Consortium know multiple putative genes and proteins involved in the REDs and\u002For affected by the drugs to be tested in RED models. These will be analyzed in patient samples from the 7 REDs to see if they are 1) expressed at all; 2) differ in expression between patient and control group and 3) are correlated with clinical endpoints and\u002For symptoms of REDs.\n\nThe 7 REDs under investigation are briefly explained as follows:\n\n1. AAK: genetic progressive limbal stem cell degeneration leading to corneal neovascularization, inflammation, recurrent erosions, chronic pain and vision loss.\n2. OCP: autoimmune scarring of the conjunctiva leads to deficient wound healing, inflammation, scarring, blindness and pain.\n3. EEC Syndrome: Ectodermal Dysplasia causes pathological corneal scarring and blindness.\n4. NK: involves a corneal nerve deficit leading to reduction or loss of corneal sensitivity, impaired wound healing, corneal ulceration and loss of vision.\n5. LSCD: acquired or hereditary stem cell deficiency inducing epithelial breakdown, neovascularization, scarring and inflammation leading to decreased vision, tearing and pain.\n6. oGvHD: a severe side-effect of successful bone-marrow transplantation leads to painful and blinding ocular surface inflammation, neovascularization and delayed wound healing.\n7. CN: in high-risk transplantation, pathologic inflammation, corneal blood and lymphatic vessels are key risk factors for high-risk corneal graft failure, leading to graft rejection and blindness.",[479,480],"Rare Diseases","Ophthalmology",[482],"Rare occular disease",{"date":360,"type":36},{"date":485,"type":36},"2026-06-01",{"date":487,"type":23},"2027-06-01",{"name":42,"class":43},{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":495,"eligibilityCriteria":496,"healthyVolunteers":12,"sex":19,"minAge":497,"maxAge":4,"enrollmentInfo":498,"targetDuration":4,"studyType":56,"phases":500,"briefSummary":501,"conditions":502,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":504,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":510},"100566817","molecular-basis-of-language-development-and-associated-disorders-100566817","NCT06660108","MOLECULAR BASIS OF LANGUAGE DEVELOPMENT AND ASSOCIATED DISORDERS","BASES MOLECULAIRES DU DEVELOPPEMENT DU LANGAGE ORAL ET DES TROUBLES SPECIFIQUES ASSOCIES","TSLO","Patients\n\nInclusion Criteria:\n\n* Eligible families included at least one child over five years old with a formal diagnosis of severe and isolated DLD according to Phase 2 CATALISE criteria . Patients have undergone age-appropriate speech, language and reading evaluations by a speech-language physician and cognitive evaluations by a neuropsychologist, as well as evaluation by a pediatric neurologist to identify co-occurring developmental disorders (ADHD, ASD…) and a medical geneticist for known genetic disorders and genetic testing recommendations. All children included received appropriate speech therapy for at least one year, with a progress report indicating the persistence of language difficulties.\n\nExclusion Criteria:\n\n* Cognitive impairment with non-verbal intellectual quotient (IQ) below 2 SD assessed with the Wechsler Preschool and Primary Scale of Intelligence (WPPSI), or the Wechsler Intelligence Scale for Children (WISC-IV or V) according to the age-appropriateness, ASD, moderate to severe hearing loss, orofacial structural abnormalities, known neurological or genetic disorders at the initial assessment. None of the patients met the diagnostic criteria for CAS according to the ASHA (American Speech-Language-Hearing Association, 2007. Childhood apraxia of speech www.asha.org\u002Fpolicy).","5 Years",{"count":499,"type":23},50,[58],"Developmental Language Disorder (DLD) refers to children who present with language difficulties that are not due to a known biomedical condition or associated with autism spectrum disorder (ASD) or intellectual disability. The prevalence of DLD is \\~7%-8% or 2% if severe forms are considered.\n\nHowever, the clinical heterogeneity of language disorders, the presence of co-morbidities and the inconsistent terminology used for many years have hindered research and clinical practice. Distinguishing sub-groups of children with language problems is crucial when tackling the underlying genetic causes of this disease. Recently, several studies using high-throughput sequencing have better define the genetic basis of CAS but such studies focusing on DLD are limited. The investigation of more homogeneous cohorts of individuals that clearly distinguish DLD cases, from ID and not including children with CAS should improve our understanding of the genetic basis of this disorder.\n\nIn this study, we aim to built and investigate a well-characterized cohort of DLD patients using pangenomic approaches to better define the molecular basis of this disorder. All individuals will be analyzed using chromosomal microarray analysis and whole genome sequencing. Multiple observations and preliminary results suggest strong links with the genetic basis of other neurodevelopmental disorders.\n\nThe goal is to identify CNV or SNV as causative allele or risk factor and already known to be involved in other neurodevelopmental disorders as well as potential new variants.",[503],"Developmental Language Disorder",{"date":360,"type":36},{"date":506,"type":36},"2025-03-25",{"date":508,"type":23},"2028-03-25",{"name":42,"class":43},3,{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":517,"eligibilityCriteria":518,"healthyVolunteers":18,"sex":19,"minAge":4,"maxAge":4,"enrollmentInfo":519,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":520,"conditions":521,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":522,"startDateStruct":523,"completionDateStruct":525,"leadSponsor":527,"locationsCount":44},"100523927","genetic-susceptibility-to-severe-infections-100523927","NCT06102070","Genetic Susceptibility to Severe Infections","Genetic Susceptibility to Severe Infections Including in Particular But Not Exhaustively All Types of Viral, Bacterialn and Fungal Infections.","PREDISPOSITI","Inclusion Criteria:\n\n* to sign the informed consent signed by the patient. In the case of a minor patient, consent is signed by the holders of parental authority. In the case of a protected adult patient, the consent is signed by their legal representative. In the case of an adult patient unable to consent at the time of inclusion, consent is signed by a family member.\n* to have a proven rare and severe infection\n* to be hospitalized or followed in a specialized hospital department, in the emergency room or in intensive care\n* to be affiliated to the French Social Security system\n* for relatives, to be related to the index case up to the 3rd degree: Parents, Children, Brother, Sister, Grandparents, Uncles, Aunts, Cousins, Nephews, Nieces\n\nExclusion Criteria\n\n* to have an acquired immunodeficiency (having received immunosuppressive treatment in the 3 months preceding the onset of the disease or being HIV positive)\n* pregnant woman at the time of illness",{"count":309,"type":23},"Only a fraction of individuals infected with microbes develop clinical disease. This observation raises fundamental questions about the pathogenesis of infectious diseases. There is a complex interaction between environmental (microbial and non-microbial) and human (genetic and non-genetic) factors. This will determine the quality of the immune response against the infectious agent and the clinical manifestation. By definition, individuals who die from an infection have defective immunity to the pathogen in question (immune agent (immune deficiency).\n\nThe investigation of individual variability in the development of infectious diseases began in the early 20th. The first evidence to support the hypothesis that individual variability variability and immune deficiencies were hereditary came from observations of familial cases or genetic isolates genetic isolates (from a homogeneous population) of rare or common infectious diseases, which in some cases Mendelian heredity hat predisposition to infectious diseases runs in families even more so than diseases associated with less determined environmental factors, such as certain cancers. such as certain cancers. Finally, studies comparing the rate of concordance of infectious diseases between monozygotic and dizygotic twins also implicate genetic factors in disease susceptibility.\n\nThese observations were validated by the discovery of genetic defects associated with severe infectious diseases, leading to proof of concept. While a number of hereditary immune deficiencies associated with susceptibility to multiple pathogens or microorganisms, a growing number of new and rare new and rare immune deficiencies conferring restricted susceptibility to infections caused by a single caused by a single pathogen family, or even a single pathogen, in otherwise healthy children, have recently been identified (one gene, one pathogen). As a result, a dozen Mendelian clinical syndromes characterized by restricted susceptibility are now known. Over the last 20 years, it has been proven that these \"idiopathic\" infections were immune deficiencies.\n\nThe investigators now wish to study new severe infections, including but not limited to viral, fungal and bacterial infections. viral, fungal, bacterial and parasitic infections. This should lead to a better understanding of the pathophysiology of each disease, the development of new therapeutics and better patient care.",[312],{"date":360,"type":36},{"date":524,"type":36},"2022-02-18",{"date":526,"type":23},"2038-10-18",{"name":42,"class":43},{"id":529,"slug":530,"hasResults":12,"nctId":531,"briefTitle":532,"officialTitle":533,"acronym":534,"eligibilityCriteria":535,"healthyVolunteers":12,"sex":19,"minAge":4,"maxAge":4,"enrollmentInfo":536,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":538,"conditions":539,"keywords":545,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":552,"startDateStruct":553,"completionDateStruct":555,"leadSponsor":557,"locationsCount":44},"100512588","national-cohort-on-congenital-defects-of-the-eye-100512588","NCT05954403","National Cohort on Congenital Defects of the Eye","National Cohort on Congenital Defects of the Eye: Natural History, Genetic Determinisms and Improved Ocular and Extra-ocular Outcome Prediction for Better Patient Management","RaDiCoACOEIL","Inclusion Criteria:\n\n* Newborns and\u002For children from birth to 7 years old, Children from 8 years old affected with the following ocular defects: anophthalmia, microphthalmia, aniridia or anterior segment dysgnesis.whose parents will have properly evaluated risks and benefits of the study and will be given an informed consent to participate the protocol.\n* Patients affiliated to the \"Régime National d'Assurance Maladie\". Inclusion of foreign patients will be possible through the French inclusion centers when they agreed to be charged for all medical fees.\n* Adults affected with the following ocular defects: anophthalmia, microphthalmia, aniridia or anterior segment dysgenesis\n* Adult patients under guardianship whose guardians will have properly evaluated risks and benefits of the study and will be given an informed consent to participate the protocol. Indeed, intellectual disability may be associated with the ocular defects and we will need to include these patients in order to evaluate incidence of this event.\n* Adult patients able to properly evaluate risks and benefits of the study and to give their informed consent to participate to the protocol.\n* Adult parents of an affected child participating to the study and willing to participate to the inheritance study (results of DNA analysis).\n* Inclusion of foreign patients will be possible through the French inclusion centres when they agreed to be charged for all medical fees.\n\nPregnant women can be included in the study\n\nExclusion Criteria:\n\n* No exclusion criteria",{"count":537,"type":23},800,"Congenital malformations of the eye comprise various developmental defects including microphthalmia, anophthalmia, aniridia, and anterior segment anomalies (such as Peters and Axenfeld-Rieger anomalies). These malformations are frequently associated with extra-ocular features and intellectual disability. However, little is known about visual outcome, frequency and consequences of extra-ocular features in patients.\n\nThe originality of the project will be to include a spectrum of malformation thought to be a phenotypic continuum (anophthalmia, microphthalmia, aniridia, anterior segment dysgnesis). In addition, we aim to conduct a 10 year follow-up of these children, thus allowing determining ocular and neurological outcomes as any other medical event. We should also be able to determine phenotypic factors that would be associated with good or poor visual and neurologic outcomes",[540,541,542,543,544],"Anophthalmia","Microphthalmia","Aniridia","Anterior Segment Dysgenesis 6, Peters Anomaly Subtype","Anterior Segment Dysgenesis 3, Rieger Subtype",[546,547,548,549,550,551],"Anophthalmia-Microphthalmia-Aniridia","anterior segment dysgenesis","Peters anomaly","Axenfeld-Rieger anomaly","Congenital malformations of the eye","Neuropsychological evaluation",{"date":360,"type":36},{"date":554,"type":36},"2017-07-11",{"date":556,"type":23},"2037-07",{"name":42,"class":43},{"id":559,"slug":560,"hasResults":12,"nctId":561,"briefTitle":562,"officialTitle":562,"acronym":563,"eligibilityCriteria":564,"healthyVolunteers":12,"sex":19,"minAge":4,"maxAge":4,"enrollmentInfo":565,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":567,"conditions":568,"keywords":570,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":573,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":577,"locationsCount":44},"100508488","european-cystinosis-cohort-100508488","NCT05901077","European Cystinosis Cohort","RaDiCo-ECYSCO","Inclusion Criteria:\n\n* Confirmed diagnosis of cystinosis (based on cystine dosage, presence of crystals at eye examination or molecular diagnosis)\n* Signed informed consent\n\nExclusion Criteria:\n\n* Patients not able to give their informed consent. No other criteria (patients with associated disease should be enrolled).",{"count":566,"type":23},400,"Cystinosis is a generalized lysosomal storage disease with a reported incidence of about 1:180,000 live births. There are estimated 110-140 cases in France (approximately 500 in Western Europe). The disease is caused by mutations in the CTNS gene coding for cystinosin, a lysosomal carrier protein. The lysosomal cystine accumulation leads to cellular dysfunction in many organs. The first symptoms start at about 6 months of age. In the absence of specific therapy, end stage renal disease occurs between 6 and 12 years of age. Survival beyond this age is associated with the development of extra-renal complications.\n\nRenal transplantation and the availability of cystine-depleting medical therapy, cysteamine (EU\u002F1\u002F97\u002F039\u002F001, EU\u002F1\u002F97\u002F039\u002F003), have radically altered the natural history of cystinosis. Cystinosis is a good example of a \"paediatric\" disease where patients now survive into adolescence and adulthood. These individuals have complex, multisystem problems that require on-going care.\n\nDespite some progress in recent years there are still significant limitations in the knowledge of diagnostic and therapeutic procedures. A first European registry was launched in 2011, using the CEMARA application developed by the Banque Nationale de Données Maladies Rares (BNDMR, CNIL authorisation number: 1187326), allowing the collection of data from France, Belgium and Italy. The objective of the current study is to translate this database into a cohort study that will allow and facilitate the collection of a wider range of data including clinical, and personal data such as quality of life data, from an increased number of European countries, improve the monitoring, data-management and analysis of the data, offer the possibility for patients to actively participate to and benefit from the study by developing a module in which patients will enter their own data on quality of life with a direct feed-back on the general results.\n\nThis project is a unique opportunity for building a consensual European academic cohort not based on company driven, \"drug-oriented\" objectives.\n\nThe cohort will collect clinical details to analyse patient outcomes thus providing audit of patient care \\& clinical effectiveness. It will be possible, through the cohort, to indicate where improvements need to be made and ultimately improve care to the highest standards.",[569],"Cystinosis",[215,571,572],"Effects of treatments","European Study",{"date":360,"type":36},{"date":575,"type":36},"2017-04-20",{"date":442,"type":23},{"name":42,"class":43},{"id":579,"slug":580,"hasResults":12,"nctId":581,"briefTitle":582,"officialTitle":583,"acronym":584,"eligibilityCriteria":585,"healthyVolunteers":12,"sex":19,"minAge":103,"maxAge":341,"enrollmentInfo":586,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":588,"conditions":589,"keywords":593,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":598,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":44},"100460583","neuroplasticity-after-proprioceptive-rehabiliation-100460583","NCT05277519","Neuroplasticity After Proprioceptive Rehabiliation","Neuroplasticity Induced by Functional Muscle Tendon Vibrations in Patients With Acquired Brain Injury","VibraLCA","Inclusion Criteria:\n\n* hemiparesis at least transient in lower limb following an acquired brain injury (stroke or traumatic brain injury)\n* French spoken\n* Affiliated to a French social insurance\n* No previous traumatic, vascular or neurodegenerative injuries\n* Having presented during the acute phase or presenting a motor deficit of one of the lower limbs\n* Presenting an absence of autonomy of walking at the entrance of the rehabilitation department\n* In the sub-acute phase, i.e. from 15 days to 6 months after the accident\n* Presenting moderate cognitive disorders allowing them to understand instructions and give their consent\n\nExclusion Criteria:\n\n* strong cognitive disorders\n* maintenance of justice, tutelage, legal guardianship\n* Pregnancy and breastfeeding\n* Outpatients who do not have weekly follow-up in the rehabilitation department",{"count":587,"type":23},56,"Sequences of muscle tendon vibrations allow to reproduce the sensory feedback during movement like locomotion and kinaesthesia. It is known that such a treatment promotes motor recovery after stroke assuming that it enhances neuroplasticity. The aim of the research is to study the activity in cerebrospinal circuitry to evaluate the neuroplastic changes during and after instrumented proprioceptive rehabilitation relying on sequences of muscle vibration in subacute stroke stages.",[590,591,592],"Stroke","Hemiparesis","Traumatic Brain Injury",[594,595,385,596,597],"Neuroplasticity","Electrophysiology","Neurophysiology","Muscle vibration",{"date":360,"type":36},{"date":600,"type":36},"2022-06-16",{"date":602,"type":23},"2027-12-15",{"name":42,"class":43},{"id":605,"slug":606,"hasResults":12,"nctId":607,"briefTitle":608,"officialTitle":609,"acronym":610,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":19,"minAge":103,"maxAge":430,"enrollmentInfo":612,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":614,"conditions":615,"keywords":618,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":622,"startDateStruct":623,"completionDateStruct":625,"leadSponsor":627,"locationsCount":69},"100396254","biomarkers-and-choroidal-neovascularization-100396254","NCT04439708","Biomarkers and Choroidal Neovascularization","Biomarkers Analysis of Mineralocortoid Receptor Activation in the Serum and Ocular Fluid of Patients With Choroidal Neovascularization","BioNéoRet","Inclusion Criteria:\n\nPatients of group 1:\n\n* Patients with type 1 choroidal neovascularization in a context of central serous chorioretinoathy or age related macular degeneration\n* Patients without intravitreal injection or last intravitreal injection \\> 3 months\n* Informed signed consent\n\nPatients of group 2:\n\n* Patients without choroidal neovascularization\n* Patients with intraocular surgery (cataract or vitrectomy surgery)\n* Signed consent\n\nExclusion Criteria:\n\n* Myocardial infarction \\\u003C 12 months\n* Chronic renal failure\n* Inflammatory disease\n* Infectious disease :HIV, viral hepatitis, tuberculosis\n* Type 1 or 2 Diabetes\n* Patients treated by mineralocorticoid antagonist treatment.\n* Type 2 or 3 choroidal neovascularization\n* Pregnant woman",{"count":613,"type":23},250,"The aim of the study is to find biomarkers in the blood and aqueous humor of patients with type 1 choroidal neovascularization and correlate them with the response to anti-VEGF treatment.",[616,617],"Choroidal Neovascularization","Mineralocorticoid Excess",[619,620,621],"central serous chorioretinopathy","age related macular degeneration","biomarker",{"date":360,"type":36},{"date":624,"type":36},"2020-07-06",{"date":626,"type":23},"2027-07-06",{"name":42,"class":43},{"id":629,"slug":630,"hasResults":12,"nctId":631,"briefTitle":632,"officialTitle":632,"acronym":633,"eligibilityCriteria":634,"healthyVolunteers":12,"sex":19,"minAge":4,"maxAge":4,"enrollmentInfo":635,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":636,"conditions":637,"keywords":638,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":642,"lastUpdatePostDateStruct":643,"startDateStruct":645,"completionDateStruct":647,"leadSponsor":649,"locationsCount":44},"100645346","european-cystinosis-cohort-2-100645346","NCT07680751","European Cystinosis Cohort 2","RaDiCo-ECYSCO2","Inclusion Criteria:\n\n* Confirmed diagnosis of cystinosis based on leukocyte cystine measurement, presence of corneal cystine crystals, and\u002For molecular genetic diagnosis\n* Signed informed consent obtained from the patient or legal representative\n\nExclusion Criteria:\n\n* Patients unable to provide informed consent or without a legal representative when required\n* No other specific exclusion criteria; patients with associated diseases may be included",{"count":613,"type":23},"This European observational cohort follows patients with cystinosis, a rare lysosomal storage disease caused by CTNS mutations leading to cystine accumulation and multisystem involvement. It aims to describe the long-term clinical course under current treatments, focusing on renal and extra-renal complications, survival, and quality of life. It also evaluates treatment effects and explores biomarkers, including inflammatory markers, with biobanking for future research.",[569],[569,639,640,572,641],"Rare disease cohort","CTNS mutation","Cysteamine treatment","2026-06-26",{"date":644,"type":36},"2026-07-02",{"date":646,"type":23},"2026-07-01",{"date":648,"type":23},"2028-03-01",{"name":42,"class":43},""]